EyePoint Pharmaceuticals (NASDAQ:EYPT) reported Q2 EPS of ($0.52), in-line with the analyst estimate of ($0.52). Revenue for the quarter came in at $11.3 million versus the consensus estimate of $10.89 million.
EyePoint Pharmaceuticals (NASDAQ:EYPT) reported Q2 EPS of ($0.52), in-line with the analyst estimate of ($0.52). Revenue for the quarter came in at $11.3 million versus the consensus estimate of $10.89 million.